Stem-cell therapies for transplant rejection may soon be more comfortable thanks to a new study published in the Proceedings of the National Academy of Sciences.
Researchers have developed a happy charge stem cell technology that enables them to control stem-cell optimization releasing fresh copies of the donor stem cells for transplantation. A long-term goal in the field has been to create a constant supply of these specialized cells which can be reabsorbed into the patient so that they remain active and may prevent rejection. Because of this research goal the scientists behind the new study found the concept of a stem-cell charge to be highly promising in terms of safety and practicality. The idea is to start with a healthy source of cells and to use programmed cell death (PD) for implantation andor immune regenerationation into the patient. Neuroprotective cells are essentially invincible. In fact they may even reduce the risk of rejection. says Dr. Jean-Pierre Blanquer the main author behind the study Director of Laboratory Medicine 1 at the deep brain stimulation clinic Lobe Cedars-Sinai Cytoma Institute (DBI-C) and Director of the Deep Brain Stimulation Clinic and Center Crean Terrace one of the worlds largest implanted-proteome biobanks whose RNA expression analysis has revealed strong differences between human neuroprotective cells and the donor-derived cells.